ArticlePloS one2026
Predicting short-term mortality in severe cirrhosis: An interpretable machine learning model integrating routine clinical indicators.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of the identified genus of anaerobic bacteria in bloodstream infection beyond host-related risk factors: a five-year retrospective cohort study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe critical need for precise risk stratification in severe liver cirrhosis is underscored by its substantial 30-day mortality rates, demanding reliable tools to guide clinical interventions.
objectiveTo establish a machine learning-driven prognostic model for short-term mortality prediction in decompensated cirrhosis through comprehensive analysis of critical care data.
methodsThis retrospective cohort study analyzed 1,044 carefully curated cases from the MIMIC-IV database, randomly divided into training (n = 740) and validation (n = 304) sets. We developed a machine learning model incorporating multidimensional clinical parameters, with rigorous evaluation and internal validation. Short-term survival was analyzed via bootstrap-validated Cox proportional hazards regression. Prognostic heterogeneity across international normalized ratio (INR)-based strata was examined.
resultsThe final prediction model incorporated eight significant predictors: age (OR 1.051, 95% CI 1.033-1.070), INR (OR 1.423, 95%CI 1.231-1.644), creatinine (OR 1.171, 95%CI 1.071-1.208), platelets (OR 0.995, 95%CI 0.993-0.997), white blood cell (OR 1.116, 95%CI 1.078-1.155), total bilirubin (OR 1.027, 95%CI 1.002-1.052), peptic ulcer (OR 0.336, 95%CI 0.134-0.845), and Aspartate Aminotransferase/Alanine Aminotransferase (AST/ALT) (OR 1.508, 95%CI 1.294-1.757). The model demonstrated excellent discrimination with an AUC of 0.846 in the training cohort. Cox regression analysis confirmed these findings and identified additional associations with aspartate aminotransferase and red blood cell levels. Furthermore, the indicators within the model provide accurate predictions for the clinical outcomes of patients suffering from severe cirrhosis. Subgroup analysis revealed significant mortality variations across different INR ranges (P < 0.001).
conclusionsOur prediction model identifies high-risk cirrhotic patients and highlights critical prognostic factors, offering clinicians a valuable tool for risk stratification and timely intervention. The strong correlation between laboratory markers, complications, and outcomes underscores the importance of close monitoring in this population. However, our model is an initial step, effective within the ICU but requiring external, multi-center studies to broaden its clinical applicability, which is a clear priority for our future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.